Revenue Breakdown
Composition ()
No data
Revenue Streams
Prestige Consumer Healthcare Inc (PBH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is North American OTC Healthcare-Women's Health, accounting for 18.5% of total sales, equivalent to $50.59M. Other significant revenue streams include North American OTC Healthcare-Gastrointestinal and North American OTC Healthcare-Dermatologicals. Understanding this composition is critical for investors evaluating how PBH navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Prestige Consumer Healthcare Inc maintains a gross margin of 53.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.06%, while the net margin is 15.40%. These profitability ratios, combined with a Return on Equity (ROE) of 11.29%, provide a clear picture of how effectively PBH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PBH competes directly with industry leaders such as VRDN and KNSA. With a market capitalization of $3.08B, it holds a significant position in the sector. When comparing efficiency, PBH's gross margin of 53.41% stands against VRDN's 100.00% and KNSA's 88.80%. Such benchmarking helps identify whether Prestige Consumer Healthcare Inc is trading at a premium or discount relative to its financial performance.
